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Background: The “smoking paradox” indicates that patients with acute ischemic stroke
(AIS) who smoke at the time of their stroke may have a better prognosis after intravenous
thrombolysis than non-smokers. However, findings are inconsistent and data analyzing
the effect of smoking on treatment efficacy of intravenous thrombolysis are scarce.
Methods: We performed a pre-specified post-hoc subgroup analysis of the Efficacy and
Safety of MRI-Based Thrombolysis in Wake-Up Stroke (WAKE-UP) trial that randomized
AIS patients with unknown time of symptom onset who had diffusion-weighted
imaging-fluid attenuation inversion recovery (DWI-FLAIR) mismatch to either alteplase or
placebo. Patients were categorized as current smokers or non-smokers (including former
smokers and never-smokers). Baseline demographic and clinical characteristics, as well
as clinical and imaging follow-up data were analyzed according to smoking status.
Results: Four hundred and eighty six patients were included in the analysis. Current
smokers (133, 27.4%) were younger (60.1 ± 13.0 vs. 67.2 ± 10.3 years; p < 0.001)
and less often had arterial hypertension (45.0% vs. 56.8%; p = 0.02) or atrial fibrillation
(3.8% vs. 15.3%; p < 0.001). The acute stroke presentation was more often due to large
vessel occlusion among current smokers (27.1 vs. 16.2%; p= 0.01), and smokers had a
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trend towards more severe strokes (National Institutes of Health Stroke Scale score>10
in 27.1% vs. 19.5%; p= 0.08). The treatment effect of alteplase, quantified as odds ratio
for a favorable outcome (modified Rankin Scale [mRS] score at 90 days of 0 or 1), did
not differ between current smokers and non-smokers (p-value for interaction: 0.59). After
adjustment for age and stroke severity, neither the proportion of patients with favorable
outcome, nor the median mRS score at 90 days differed between current smokers and
non-smokers. When additional potential confounders were included in the model, the
median mRS score was higher in current smokers than in non-smokers (cOR of better
outcome for current smokers vs. non-smokers: 0.664 [0.451–0.978], p = 0.04).
Conclusions: In patients with mild to moderate MRI-proven AIS and unknown time
of symptom onset with DWI-FLAIR mismatch, current smokers had worse functional
outcome as compared to non-smokers. Current smoking did not modify the treatment
effect of alteplase.
Clinical Trial registration: Main trial (WAKE-UP): ClinicalTrials.gov, NCT01525290; and
EudraCT, 2011-005906-32. Registered 02 February 2012.
Keywords: ischemic stroke, thrombolysis (tPA), acute therapy, smoking, treatment outcome and efficacy,
cerebrovascular diseases
INTRODUCTION
Intravenous thrombolysis with recombinant tissue plasminogen
activator (alteplase) is an effective treatment option for eligible
patients with acute ischemic stroke (AIS) that improves
functional outcome (1, 2) and reduces long-term disability (3).
Knowledge of the risk/benefit profile of intravenous thrombolysis
in specific patient groups may aid in individualizing treatment
decisions. There is conflicting evidence in the literature as to
whether current smoking is associated with a better prognosis
in patients with AIS treated with alteplase (4–9). More
importantly, there are no data that describe the potential effect
of current smoking as a treatment effect modifier of intravenous
thrombolysis with alteplase in patients with MRI-proven AIS.
In the NINDS t-PA stroke trial, a subgroup analysis of which
indicated that there was no interaction between current smoking
and treatment effect of alteplase (10), AIS was defined clinically
without confirmatory MRI (11). It has been hypothesized that
current smoking may modify the treatment effect of alteplase
by lowering levels of endogenous tissue plasminogen activator.
This would induce a hypercoagulable state which in turn favors
the formation of fibrin-rich thrombi that are more susceptible to
fibrinolytic treatment (12).
In the current study, we examined whether smoking status
at the time of stroke occurrence modified the treatment effect
of alteplase in terms of functional recovery in patients with AIS
enrolled in the Efficacy and Safety of MRI-Based Thrombolysis in
Wake-Up Stroke (WAKE-UP) trial (13).
Abbreviations: AIS, acute ischemic stroke; DWI, diffusion-weighted imaging;
FLAIR, fluid attenuated inversion recovery; IQR, interquartile range; MRI,
magnetic resonance imaging; mRS, modified Rankin scale; NIHSS, National
Institutes of Health Stroke Scale (score); OR, odds ratio; SD, standard deviation.
MATERIALS AND METHODS
Participants and Trial Design
WAKE-UP was a multi-center, two-arms, interventional,
prospective, double blind, randomized controlled trial that
compared the effect of treatment with alteplase and placebo
in patients with AIS and unknown time of symptom onset
in whom magnetic resonance imaging (MRI) suggested that
the stroke had occurred within a time window of 4.5 h. The
detailed protocol and the main results have been published
previously (13). Patients aged 18–80 years old were enrolled
and randomized in a 1:1 ratio to treatment with either alteplase
at a dose of 0.9 mg/kg body weight or placebo if they had no
known contraindications (except unknown time of symptom
onset), were independent in their daily living before the stroke
incident, were not planned to receive mechanical thrombectomy,
and exhibited a diffusion-weighted imaging-fluid attenuated
inversion recovery (DWI-FLAIR) mismatch on acute MRI.
Patients were recruited 70 experienced stroke research centers
in Europe (13). Randomization occurred by means of a Web-
based procedure with a permuted-block design according to
trial center. During the ascertainment of clinical and baseline
characteristics, patients were asked about smoking status.
Response options included “current smoker” (regular tobacco
use within the last 12 months), “ex-smoker” (no tobacco
use within the last 12 months), and “never-smoker.” For
all analyses, never-smokers and ex-smokers were combined
into a single group of (current) non-smokers to increase
statistical power.
Outcome Measures
The main outcome measure in our analysis was the modification
of the treatment effect of alteplase as compared to placebo
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associated with smoking status. The treatment effect of
alteplase was quantified as the odds ratio (OR) of a favorable
outcome at 90 days as determined by a score of 0 or
1 on the modified Rankin scale (mRS, scale ranging from
0 to 6, with higher scores reflecting higher degree of
disability), or as the common OR of improved functional
outcome in an ordinal mRS shift analysis. Secondary outcome
measures were functional outcome at 90 days and the
occurrence of hemorrhagic complications or death stratified by
smoking status.
Statistical Analysis
Continuous variables are presented as mean ± standard
deviation (SD) or as median and interquartile range (IQR).
Categorical data are presented as counts and percentages.
Between-group differences were tested for statistical significance
in both univariate analyses and multivariate analyses adjusted
for age and baseline stroke symptom severity (National
Institutes of Health Stroke Scale [NIHSS] score) using chi-
squared tests, Student’s t-tests, Wilcoxon–Mann–Whitney U
test, and binary and cumulative logit models. The treatment
effect of alteplase was expressed as an OR or common
OR with 95% confidence intervals and calculated using an
unconditional logistic-regression model or a proportional-
odds logistic-regression, respectively, adjusted for the two
randomization strata (age and baseline NIHSS score, pre-
specified). Large vessel occlusion included occlusion of the
internal carotid artery; middle, anterior, and posterior cerebral
artery; basilar artery; and vertebral artery and was determined
based on acute magnetic resonance angiography by the central
reading board. Modification of the treatment effect by smoking
status was assessed by looking at the interactive term. A two-
sided alpha-level of 0.05 was considered statistically significant.
As a post-hoc addition to the analysis plan, we repeated the
multivariate analyses including factors that were distributed
unevenly between the two groups (p < 0.05) as additional
covariates, namely age as a continuous variable, the presence of
proximal large vessel occlusion at baseline, medical history of
atrial fibrillation, and medical history of arterial hypertension.
In addition, we performed exploratory analyses of the effect of
ever-smoking (combining current smokers and ex-smokers) vs.
never-smoking (never-smokers) on outcome and treatment effect
of alteplase.
Ethics Approval and Informed Consent
The WAKE-UP trial protocol was approved by the national
regulatory authority in each participating country. The trial was
approved by the respective national or local ethics committees or
institutional review boards. Patients or their legal representatives
provided written informed consent according to national and
local regulations. The subgroup analysis with regard to smoking
status presented in this paper was approved by the trial
steering committee. The data that support the findings of this
study are available from Dr. Thomalla (thomalla@uke.de) upon
reasonable request.
RESULTS
Patient Characteristics at Baseline
Information on smoking status was available for 486 of 503
patients (96.6%), of whom 230 (47.3%) were classified as never-
smokers, 123 (25.3%) as ex-smokers, and 133 (27.4%) as current
smokers. Demographic and clinical characteristics of all patients
at baseline according to smoking status are shown in Table 1.
Patients in the current-smokers group were, on average, younger
(mean age 60.1 ± 13.0 vs. 67.2 ± 10.3; p < 0.001) and less often
had amedical history of arterial hypertension (45.0 vs. 56.8%; p=
0.02) or atrial fibrillation (3.8 vs. 15.3%; p < 0.001). At the acute
stroke presentation, current smokers more frequently had large
vessel occlusion than non-smokers (27.1 vs. 16.2%; p = 0.01).
TABLE 1 | Demographic and clinical characteristics at baseline according to
smoking status.
Variable Non-smokers
(n = 353)
Current smokers
(n = 133)
P-value*
Mean age ± SD—years 67.2 ± 10.3 60.1 ± 13.0 <0.001
Male sex—no./total no. (%) 221/353 (62.6) 91/133 (68.4) 0.24
Reason for unknown time of symptom onset—no./total no. (%)
Nighttime sleep 320/353 (90.7) 115/133 (86.5) 0.35
Daytime sleep 13/353 (3.7) 10/133 (7.5)
Aphasia, confusion, or other 20/353 (5.7) 7/133 (5.3)
Median interval between last
time the patient was known to
be well and symptom recognition
(IQR)—hours
7.3 (4.8–8.9) 7.0 (4.8 – 8.8) 0.63
Medical history—no./total no. (%)
Arterial hypertension 200/352 (56.8) 59/131 (45.0) 0.02
Diabetes mellitus 56/349 (16.0) 25/132 (18.9) 0.78
Hypercholesterolemia 128/337 (38.0) 50/130 (38.5) 0.57
Atrial fibrillation 53/346 (15.3) 5/132 (3.8) <0.001
History of ischemic stroke 45/352 (12.8) 22/133 (16.5) 0.49
Median NIHSS score (IQR) 5 (4–9) 6 (4–11) 0.34
NIHSS score, stratified—no./total no. (%)
≤10 284/353 (80.5) 97/133 (72.9) 0.08
>10 69/353 (19.5) 36/133 (27.1)
Median lesion volume on
diffusion-weighted imaging
(IQR)—ml
2.2 (07–7.5) 2.2 (0.9–10.0) 0.33
Any large vessel occlusion on
time-of-flight magnetic
resonance angiography—no.
(%)†
55/340 (16.2) 35/129 (27.1) 0.01
Median time from symptom
recognition to treatment initiation
(IQR)—hr
3.2 (2.5–3.9) 3.0 (2.5–3.7) 0.34
Interval between last time that
the patient was last known to be
well and treatment initiation
(IQR)—hr
10.5 (8.1–12.1) 10.1 (8.1–12.1) 0.51
*P-value not adjusted for multiple testing.
†
Includes occlusion of the internal carotid artery;
middle, anterior, and posterior cerebral artery; basilar artery; and vertebral artery. SD
stands for standard deviation; IQR, interquartile range; NIHSS, National Institutes of Health
Stroke Scale; MRI, magnetic resonance imaging.
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FIGURE 1 | Distribution of scores on the modified Rankin scale at 90 days
according to smoking status.
In addition, there was a trend for current-smokers to be more
likely to present with more severe strokes (NIHSS score >10;
27.1 vs. 19.5%; p = 0.08), although median NIHSS scores did
not differ. The remaining parameters, including imaging findings
and procedural time intervals, were similar between the groups of
current smokers and non-smokers.
Prognostic Value of Current Smoking
Status—Follow-Up Data
In univariate analyses, fewer patients in the group of current
smokers than in the group of non-smokers had a favorable
outcome (mRS score 0–1), but this difference did not reach
statistical significance (40.8 vs. 50.6%; p = 0.06). Similarly,
the median mRS score at day 90 tended to be higher in
current smokers than in non-smokers (2 [1–3] vs. 1 [1–3]). The
distribution of mRS scores at 90 days according to smoking status
is shown in Figure 1. After adjustment for age and initial NIHSS
score, there was no statistically significant difference between
current smokers and non-smokers with regards to the proportion
of favorable outcome at 90 days (OR for current smokers vs. non-
smokers: 0.728 [0.462–1.148], p = 0.13) or the distribution of
mRS scores at 90 days (mRS shift analysis; common OR of better
outcome for current smokers vs. non-smokers: 0.828 [0.569–
1.203], p = 0.32). When age taken as a continuous variable,
the presence of proximal large vessel occlusion at baseline and
medical history of atrial fibrillation and arterial hypertension
were included as additional covariates in the regression model,
the difference in the distribution of mRS scores at 90 days
between current smokers and non-smokers reached statistical
significance (mRS shift analysis; common OR of better outcome
for current smokers vs. non-smokers: 0.664 [0.451–0.978], p =
0.04). No significant between-group differences were observed
for deaths at 90 days or for signs of intracranial hemorrhage,
symptomatic hemorrhage, new ischemic lesions, and space
occupying infarctions as detected by MRI (Table 2).
Treatment Effect of Alteplase According to
Smoking Status
In the total patient sample, multivariate analyses adjusted for
age and initial NIHSS score strata showed that treatment with
alteplase as compared to placebo was associated with a higher
proportion of patients with favorable outcome in dichotomized
as well as in mRS shift analysis (OR 1.61 [1.09–2.36], p = 0.02;
TABLE 2 | Safety outcomes according to smoking status.
Variable Non-smokers
(n = 353)
Current
smokers
(n = 133)
P-value*
Any signs of intracranial
hemorrhage—no./total no. (%)
64/345 (18.6) 21/132 (15.9) 0.93
Symptomatic
hemorrhage—no./total no. (%)
9/347 (2.6) 1/132 (0.8) 0.30
New ischemic lesions—no./total
no. (%)
116/346 (33.5) 39/129 (29.8) 0.45
Space occupying
infarctions—no./total no. (%)
33/346 (9.5) 8/131 (6.1) 0.28
*P-value not adjusted for multiple testing.
and 1.62 [1.17–2.23], p = 0.003, respectively). This treatment
effect of alteplase was not different in the group of current
smokers and non-smokers (p-value for interaction: 0.59 and 0.49,
respectively; Figure 2). Similar results were obtained when age
(continuous), the presence of proximal large vessel occlusion
at baseline and medical history of atrial fibrillation and arterial
hypertension were included as additional covariates.
Exploratory Analyses of Ever-Smokers vs.
Never-Smokers
When comparing ever-smokers (combined groups of current
smokers and ex-smokers; n= 230) with never-smokers (n= 256),
ever-smokers were significantly younger (mean age 64.2 ± 12.1
vs. 66.5 ± 10.8; p = 0.04); more often male (70.3 vs. 57.4%; p
< 0.01); more often had a history of hypercholesterolemia (43.4
vs. 32.1%, p = 0.02) and ischemic stroke (18.4 vs. 8.7%; p <
0.01); and less often had a history of atrial fibrillation (8.3 vs.
16.4%; p = 0.02). The remaining baseline characteristics were
balanced between the two groups. When adjusting for between
group differences at baseline, the rate of favorable functional
outcome was similar in both groups (48.9 vs. 47%; p = 0.94).
The point estimate for the treatment effect of alteplase was higher
in the group of ever-smokers than in never-smokers (OR 2.700
[1.520–4.795] vs. 0.913 [0.501–1.665]; p-value for interaction =
0.01). The confidence intervals in both groups overlapped and
contained the point estimate of the treatment effect of alteplase
in the total patient sample (1.61).
DISCUSSION
We performed a subgroup analysis of the WAKE-UP trial data
to investigate the relationship between smoking status and the
treatment effect of alteplase. In this study, current smoking
did not modify the treatment effect of alteplase in comparison
to placebo in patients with AIS with DWI-FLAIR mismatch
on MRI.
Patients in the current-smoker group were significantly
younger and more often presented with large vessel occlusion,
in line with a recent report (14). These associations may be
explained by accelerated smoking-induced atheroma formation
(15), the pro-coagulatory effects of smoking (16), or different
smoking habits in older and younger individuals (17).
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FIGURE 2 | Treatment efficacy of i.v. thrombolysis according to smoking status. Shown are odds ratios for favorable outcome (modified Rankin Scale score 0–1) in
current smokers and non-smokers as well as in all participants. *P-value for the test of interaction between treatment group and smoking status. CI stands for
confidence interval.
The so-called “smoking paradox” refers to the prognostic
value of current smoking in patients with AIS treated with
alteplase. While some studies have reported an independent
beneficial effect of current smoking on functional outcome
and mortality (4–6), others have failed to demonstrate such
an association after adjustment for confounding covariates (7–
9). Data showing an association between current smoking and
recanalization of arterial occlusion by means of intravenous
thrombolysis (12, 18), intra-arterial thrombolysis (19), or
endovascular thrombectomy (20) are more consistent. In
contrast to previous studies, data used for the current analysis
were collected prospectively and outcome was ascertained in
a double-blinded fashion as part of a multicenter randomized
controlled trial. All included patients had acute ischemic lesions
on MRI. In the population examined for this study, we did not
find evidence of better functional outcome in current smokers
as compared to non-smokers; if anything, there was a trend for
current smokers to have worse functional outcome than non-
smokers in adjusted mRS shift analyses. For the first time, we
were able to investigate not only the prognostic value of current
smoking with regards to clinical outcome, but also its potential
to modify the treatment efficacy of alteplase as compared to
placebo in patients with MRI-proven AIS, which might be a
clinically more relevant parameter that could be used for the
individualization of treatment decisions. In line with a previous
study that examined the effect of smoking in patients selected
on the basis of clinical findings and CT-imaging (10), we did
not observe any heterogeneity between current smokers and
non-smokers with regards to the treatment effect of alteplase.
Patients planned for endovascular treatment and patients
unable to undergo MRI were excluded from WAKE-UP.
Therefore, a relatively small proportion of patients had severe
stroke symptoms with an NIHSS score > 10. Assuming that
active smoking would modify the treatment effect of alteplase
preferentially through improved recanalization rates of proximal
large vessel occlusion, this association could have been missed
in our study due to the small number of patients with proximal
large vessel occlusion. Information on recanalization of proximal
large vessel occlusions was not available for the current analysis;
however, given currently reported recanalization rates of ∼20%
with alteplase alone (21, 22) event rates in the defined subgroups
would have been too low to detect differences between current
smokers and non-smokers.
In our analysis, large vessel occlusion was more frequently
found in current smokers than in non-smokers. This association
has been reported previously by Hendrix et al. (14) in a cohort
of 1,654 AIS patients. Evidence by Ntaios et al. (23) indicating
that current smoking is predictive of large-artery atherosclerotic
stroke etiology rather than microangiopathic stroke combined
with the observation that large-artery atherosclerosis represents
a major source of large vessel occlusion could explain
this association.
Additional exploratory analyses comparing ever-smokers with
never-smokers suggested a possible beneficial effect of life-time
tobacco exposure on the treatment effect of alteplase. Although
the p-value for interaction between smoking status (ever-smokers
vs. never-smokers) and treatment assignment was statistically
significant, the confidence intervals for the treatment effect in
the groups of ever-smokers and never-smokers overlapped and
both confidence intervals contained the point estimate of the
treatment effect in the total patient sample. In addition, the
analysis was added post-hoc to the analysis plan, which raises
the possibility of a type 1 (false positive) error. Nonetheless,
lifetime tobacco exposure could lead to vascular alterations
of the cerebral circulation such as accelerated formation of
arteriosclerosis and atherosclerosis with disturbed endothelial
function that may affect the treatment effect of alteplase. Further
studies investigating the relationship between ever-smoking vs.
never-smoking and the efficacy of thrombolysis are needed.
Currently, the results of this exploratory analysis should not
affect the decision for or against treatment with intravenous
thrombolysis using alteplase in never-smokers.
The following limitations need to be considered when
interpreting the findings of our study. First, our study only
included patients with AIS and unknown time of symptom
onset, mostly nighttime stroke; therefore, our findings may not
be generalizable to witnessed strokes occurring during daytime.
Second, all patients had to be able to undergo MRI; therefore,
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our findings may not be generalizable to patients without MRI
evaluation. Third, no data was available on the amount or
frequency of smoking, nor the specific type of tobacco product
utilized. Finally, although patients in our study were randomized
to treatment with alteplase or placebo, no randomization
was performed with regards to smoking; therefore, even after
adjustment for potential confounders in multivariate analyses
residual confounding may be present.
CONCLUSIONS
In conclusion, current smokers suffered their strokes at a
younger age and more often presented initially with large
vessel occlusion and more severe strokes. After adjustment
for baseline differences, current smokers had a trend toward
worse functional outcome as compared to non-smokers. We
found no significant interaction between the treatment effect of
alteplase and current smoking status. If the postulated “smoking
paradox” does indeed exist, it may be limited to patients with
large vessel occlusion. Further studies involving a larger number
of more severely affected patients are warranted to investigate
this hypothesis.
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